Abstract
Importance Recent findings have raised concerns about an association between semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), and non-arteritic anterior ischemic optic neuropathy (NAION).
Objective To further investigate the putative association between semaglutide use and NAION.
Design Bi-national active comparator new-user cohort study with propensity score weighing to adjust for confounding, fixed-effect meta-analysis, and a supplementary self-controlled analysis (symmetry analysis).
Setting Data were obtained from national health registries in Denmark and Norway, including prescription registries, patient registries, and civil registration systems.
Participants New users of semaglutide and sodium-glucose co-transporter 2 inhibitors (SGLT-2is) during 2018-2022 (Norway) and 2018-2024 (Denmark).
Exposures Initiation of semaglutide and SGLT-2is for the management of type 2 diabetes was assessed in the main analysis. In the self-controlled design, exposure to semaglutide, regardless of indication, was investigated.
Main Outcomes and Measures Incidence rates of NAION among semaglutide and SGLT-2is users, along with hazard ratios (HRs) and incidence rate differences (IRDs) with robust 95% confidence intervals. Estimates from Denmark and Norway were pooled using a fixed-effects model (inverse variance weighting). The supplementary self-controlled study returned sequence symmetry ratios (SRs).
Results We identified 44,517 eligible users of semaglutide for the management of type 2 diabetes in Denmark and 16,860 in Norway. In total, we observed 32 NAION events among semaglutide users (24 in Denmark and 8 in Norway). This yielded an unadjusted incidence rate of NAION of 2.19/10,000 person-years among Danish semaglutide initiators, compared to 1.18 among SGLT-2i initiators. The corresponding unadjusted incidence rates in Norway were 2.90 and 0.92. After adjustment, we obtained a pooled HR of 2.81 (95% CI 1.67 to 4.75) and IRD of +1.41 (95% CI +0.53 to +2.29). Estimates were compatible in the individual countries, although with higher and less precise estimates in Norway (HR 7.25; 95% CI 2.34 to 22.4) compared to Denmark (HR 2.17; 95% CI 1.20 to 3.92). Results were consistent across sensitivity and supplementary analysis, with a notably stronger association observed in a post hoc per-protocol analysis (HR 6.35; 95% CI 2.88 to 14.0). In the supplementary self-controlled study, SRs for NAION were 1.14 (95% CI 0.55 to 2.36) in Denmark and 2.67 (95% CI 0.91 to 8.99) in Norway.
Conclusions and Relevance Our findings show an association between use of semaglutide for type 2 diabetes and risk of NAION. However, the absolute risk remains low.
Question Is there an association between semaglutide use and risk of non-arteritic anterior ischemic optic neuropathy (NAION)?
Findings In this cohort study conducted in Denmark and Norway, use of semaglutide was associated with an increased risk of NAION; the pooled hazard ratio was 2.81 (95% confidence interval (CI) 1.67 to 4.75) and the incidence rate difference (absolute risk increase) was +1.41 (95% CI +0.53 to +2.29) NAION events per 10,000 person-years. The finding was consistent across sensitivity and supplementary analysis.
Meaning Our study confirms that use of semaglutide is associated to an increased risk of NAION, but also that the excess absolute risk is low.
Competing Interest Statement
Lars Christian Lund has taught a full-day course in epidemiological methods in drug safety surveillance at Novo Nordisk, with funds paid to University of Southern Denmark (no personal fees). Vidar Hjellvik reports participation in research projects funded by Novo Nordisk and LEO Pharma, all regulator-mandated phase IV-studies with funds paid to the institution where he is employed (no personal fees), and with no relation to the work reported in this paper. Steffen Hamann has received grants from Rigshospitalet and the VELUX Foundation. None of these grants have any relation to the work reported in this paper. Oystein Kalsnes Jorstad has received a grant from Roche for developing an educational application. He receives royalties from SJJ Solutions for a syringe used in intravitreal injections. He has received consulting fees from SJJ Solutions and Oslo Economics. He has also received lecture fees from Allergan, Bayer, and Chiesi Farmaceutici, as well as support for meetings, travel, and attendance from SJJ Solutions. He holds patents for a needle for intravitreal injections and a glaucoma stent. Jorstad is also a member of the advisory boards for Allergan, Bayer, and Roche. None of these relationships have any relation to the work reported in this paper. Oystein Karlstad reports participation in research projects funded by Sanofi, Bristol Myers Squibb, Novo Nordisk, and LEO Pharma, all regulator-mandated phase IV-studies with funds paid to the institution where he is employed (no personal fees), and with no relation to the work reported in this paper. Anton Pottegard reports participation in research projects funded by Alcon, Almirall, Astellas, Astra-Zeneca, Boehringer-Ingelheim, Novo Nordisk, Servier, and LEO Pharma, all regulator-mandated phase IV-studies with funds paid to the institution where he is employed (no personal fees). Further, his research group has received one unrestricted grant from Novo Nordisk. None of these grants have any relation to the work reported in this paper. Remaining authors report no conflicts of interest.
Clinical Protocols
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Norwegian study was approved by the Regional Ethics Committee Sor-Ost B (28748, 2019/1175). Ethical approval is not required in Denmark for purely registry-based studies. The Danish study was registered at the repository of the University of Southern Denmark (11.570) and data access was granted by the Danish Health Data Authority (FSEID-6047).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
